Cancer Research: Attacking Cancer Through Activating “Big Eaters” of the Immune System

In an interview with TechnologyNetworks: Cancer Research, Pheast Therapeutics’ CEO Roy Maute outlines how macrophage checkpoint inhibition seeks to activate the innate immune system’s“big eaters” by blocking tumor-derived “don’t eat me” signals such as CD24, thereby restoring macrophage-mediated tumor clearance. The article explains the scientific rationale behind targeting CD24 and how this approach builds on the success of T-cell checkpoint inhibitors while addressing unmet needs in solidtumors, highlighting Pheast’s strategy to deliver differentiated immunotherapies.

Read the full article here.

‍